BiomEdit initiates final field safety trial for non-antibiotic biologic

A first-of-its-kind biologic

BE-101 is a first-of-its-kind probiotic vectored antibody (pvAb) biologic engineered to neutralize Clostridium perfringens toxins, a primary driver of NE-related mortality and production losses.

NE remains one of the most economically significant diseases in broiler production, with global losses estimated at USD 6 billion annually.

Recent findings published in npj Biofilms and Microbiomes, a Nature portfolio journal, showed that BE-101 significantly improved feed conversion under sub-clinical NE challenge conditions. These results also demonstrated measurable gains in body weight, reinforcing BE-101’s potential as a breakthrough non-antibiotic solution for broiler production.

Birds receiving BE-101 achieved a 6- to 7-point improvement in feed conversion ratio at key time points, along with increased finished weight and reduced NE mortality compared to challenged controls.

The study also identified improvements in gut health and host response, linking toxin neutralization to measurable production benefits.

Industry engagement and outlook

“As we continue to meet key milestones on the path toward conditional licensure, we’re focused on the day we can bring this non-antibiotic solution to producers facing a disease where new solutions are needed,” said Aaron Schacht, CEO of BiomEdit.

“Working directly with poultry producers during these field safety trials provides a real-world window into how the product performs on-farm. We’re encouraged by the engagement and the opportunity to deliver a practical tool that supports both flock health and production performance.”